Sclerostin: Just one more player in renal bone disease?

Clinical Journal of the American Society of Nephrology

Volumn 6, Issue 4, 2011, Pages 700-703

  Drüeke, Tilman B ^a   Lafage Proust, Marie Hélène ^b  

^a INSERM   (France)

^b UNIVERSITÉ DE LYON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; PARATHYROID HORMONE; SCLEROSTIN;

APOPTOSIS; BONE BIOPSY; CARTILAGE CELL; CELL DIFFERENTIATION; CELL PROLIFERATION; CHRONIC KIDNEY DISEASE; EDITORIAL; GENE MUTATION; HEMODIALYSIS; HUMAN; OSSIFICATION; OSTEOCYTE; OSTEOSCLEROSIS; PROTEIN EXPRESSION; RENAL OSTEODYSTROPHY;

BONE MORPHOGENETIC PROTEINS; CHRONIC DISEASE; GENETIC MARKERS; HUMANS; KIDNEY DISEASES; PARATHYROID HORMONE; RENAL OSTEODYSTROPHY; RNA, MESSENGER;

EID: 79955570961     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.01370211     Document Type: Editorial

References (30)

1. Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G, Kidney Disease: Improving Global Outcomes (KDIGO): Definition, evaluation, and classification of renal osteodystrophy: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 69: 1945-1953, 2006
2. Dooley AC, Weiss NS, Kestenbaum B: Increased risk of hip fracture among men with CKD. Am J Kidney Dis 51: 38-44, 2008
3. Jadoul M, Albert JM, Akiba T, Akizawa T, Arab L, Bragg-Gresham JL, Mason N, Prutz KG, Young EW, Pisoni RL: Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Kidney Int 70: 1358-1366, 2006
4. Kinsella S, Chavrimootoo S, Molloy MG, Eustace JA: Moderate chronic kidney disease in women is associated with fracture occurrence independently of osteoporosis. Nephron Clin Pract 116: c256-c262, 2010
5. Nickolas TL, Leonard MB, Shane E: Chronic kidney disease and bone fracture: A growing concern. Kidney Int 74: 721-731, 2008
6. Toussaint ND, Elder GJ, Kerr PG: A rational guide to reducing fracture risk in dialysis patients. Semin Dial 23: 43-54, 2010
7. Ott SM: New aspects of bone biology. In: The Spectrum of Mineral and Bone Disease in Chronic Kidney Disease, 2nd Ed., edited by Olgaard K, Salusky IB, Silver J, Oxford, Oxford University Press, 2010, pp 15-30
8. Ferreira A, Saraiva M, Behets G, Macedo A, Galvão M, DHaese P, Drüeke TB Evaluation of bone remodeling in hemodialysis patients: Serum biochemistry, circulating cyto-kines and bone histomorphometry. J Nephrol 22: 783-793, 2009
9. Santos FR, Moyses RM, Montenegro FL, Jorgetti V, Noronha IL: IL-1beta, TNF-alpha, TGF-beta, and bFGF expression in bone biopsies before and after parathyroidectomy. Kidney Int 63: 899-907, 2003
10. Krieger NS, Frick KK, Bushinsky DA: Mechanism of acid-induced bone resorption. Curr Opin Nephrol Hypertens 13: 423-436, 2004
11. Andress DL: Adynamic bone in patients with chronic kidney disease. Kidney Int 73: 1345-1354, 2008
12. Barreto FC, Barreto DV, Liabeuf S, Drueke TB, Massy ZA: Effects of uremic toxins on vascular and bone remodeling. Semin Dial 22: 433-437, 2009
13. Iwasaki Y, Yamato H, Nii-Kono T, Fujieda A, Uchida M, Ho-sokawa A, Motojima M, Fukagawa M: Uremic toxin and bone metabolism. J Bone Miner Metab 24: 172-175, 2006
14. Drueke T, Lieberherr M, Cournot G: Pathophysiology of aluminum-induced bone disease. Contrib Nephrol 64: 109-112, 1988
15. Schrooten I, Behets GJ, Cabrera WE, Vercauteren SR, Lamberts LV, Verberckmoes SC, Bervoets AJ, Dams G, Goodman WG, De Broe ME, D'Haese PC: Dose-dependent effects of strontium on bone of chronic renal failure rats. Kidney Int 63: 927-935, 2003
16. Dargent-Molina P, Sabia S, Touvier M, Kesse E, Breart G, Clavel-Chapelon F, Boutron-Ruault MC: Proteins, dietary acid load, and calcium and risk of postmenopausal fractures in the E3N French women prospective study. J Bone Miner Res 23: 1915-1922, 2008
17. Lafage-Proust MH, Combe C, Barthe N, Aparicio M: Bone mass and dynamic parathyroid function according to bone histology in nondialyzed uremic patients after long-term protein and phosphorus restriction. J Clin Endocrinol Metab 84: 512-519, 1999
18. Cejka D, Herberth J, Branscum AJ, Fardo DW, Monier-Faugere MC, Diarra D, Haas M, Malluche HH: Sclerostin and Dickkopf-1 in renal osteodystrophy. Clin J Am Soc Nephrol December 16, 2010 [epub ahead of print]
19. Moester MJ, Papapoulos SE, Lowik CW, van Bezooijen RL: Sclerostin: Current knowledge and future perspectives. Calcif Tissue Int 87: 99-107, 2010
20. Yadav VK, Ryu JH, Suda N, Tanaka KF, Gingrich JA, Schütz G,Glorieux FH, Chiang CY, Zajac JD, Insogna KL, Mann JJ, Hen R, Ducy P, Karsenty G: Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell 135: 825-837, 2008
21. Krause C, Korchynskyi O, de Rooij K, Weidauer SE, de Gorter DJ, van Bezooijen RL, Hatsell S, Economides AN, Mueller TD, Löwik CW, ten Dijke P: Distinct modes of inhibition by sclerostin on bone morphogenetic protein and Wnt signaling pathways. J Biol Chem 285: 41614-41626, 2010
22. Kramer I, Keller H, Leupin O, Kneissel M: Does osteocytic SOST suppression mediate PTH bone anabolism? Trends En-docrinol Metab 21: 237-244, 2010
23. Modder UI, Clowes JA, Hoey K, Peterson JM, McCready L, Oursler MJ, Riggs BL, Khosla S: Regulation of circulating sclerostin levels by sex steroids in women and in men. J Bone Miner Res 26: 27-34, 2011
24. van Lierop AH, Witteveen JE, Hamdy NA, Papapoulos SE: Patients with primary hyperparathyroidism have lower circulating sclerostin levels than euparathyroid controls. Eur J En-docrinol 163: 833-837, 2010
25. Drake MT, Srinivasan B, Mödder UI, Peterson JM, McCready LK, Riggs BL, Dwyer D, Stolina M, Kostenuik P, Khosla S: Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. J Clin Endocrinol Metab 95: 5056-5062, 2010
26. Mirza FS, Padhi ID, Raisz LG, Lorenzo JA: Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women. J Clin Endocrinol Metab 95: 1991-1997, 2010
27. Coen G, Ballanti P, Bonucci E, Calabria S, Centorrino M, Fassino V, Manni M, Mantella D, Mazzaferro S, Napoletano I, Sardella D, Taggi F: Bone markers in the diagnosis of low turnover osteodystrophy in haemodialysis patients. Nephrol Dial Transplant 13: 2294-2302, 1998
28. Li X, Ominsky MS, Warmington KS, Morony S, Gong J, Cao J, Gao Y, Shalhoub V, Tipton B, Haldankar R, Chen Q, Winters A, Boone T, Geng Z, Niu QT, Ke HZ, Kostenuik PJ, Si-monet WS, Lacey DL, Paszty C: Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res 24: 578-588, 2009
29. Iwasaki Y, Yamato H, Padhi D, Jang G, Stouch B, Fang L, Posvar E: Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 26: 19-26, 2011
30. Nii-Kono T, Fujieda A, Uchida M, Ho-sokawa A, Motojima M, Fukagawa M: Insufficiency of PTH action on bone in uremia. Kidney Int Suppl (102): S34-S36, 2006